Plasma Cell Leukemia Clinical Trials

17 recruiting

Plasma Cell Leukemia Trials at a Glance

25 actively recruiting trials for plasma cell leukemia are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Tianjin, Minneapolis, and Thessaloniki. Lead sponsors running plasma cell leukemia studies include Institute of Hematology & Blood Diseases Hospital, China, Masonic Cancer Center, University of Minnesota, and The First Affiliated Hospital of Soochow University.

Browse plasma cell leukemia trials by phase

Treatments under study

About Plasma Cell Leukemia Clinical Trials

Looking for clinical trials for Plasma Cell Leukemia? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plasma Cell Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plasma Cell Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086
Recruiting
Phase 2

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Chronic Lymphocytic LeukemiaFollicular LymphomaSmall Lymphocytic Lymphoma+8 more
Masonic Cancer Center, University of Minnesota200 enrolled1 locationNCT01962636
Recruiting
Phase 2

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05870917
Recruiting

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

Multiple MyelomaAmyloidosisPlasma Cell Leukemia
University of Alabama at Birmingham5,000 enrolled1 locationNCT05556928
Recruiting

European Myeloma Network (EMN) Sample Project

Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting
Phase 2

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

Multiple MyelomaPlasma Cell Leukemia
University of Utah40 enrolled1 locationNCT06517017
Recruiting

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+6 more
UNC Lineberger Comprehensive Cancer Center2,000 enrolled1 locationNCT03717844
Recruiting
Early Phase 1

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Phase 1Phase 2

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Early Phase 1

A Study of CT0596 in Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China27 enrolled1 locationNCT06988059
Recruiting
Phase 2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106684
Recruiting
Phase 2

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05979363
Recruiting
Early Phase 1

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Anhui Provincial Hospital36 enrolled1 locationNCT07085559
Recruiting
Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+13 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793
Recruiting
Phase 2

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple MyelomaPrimary Plasma Cell LeukemiaExtramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology54 enrolled1 locationNCT06140966